Thermo Fisher Scientific announces crucial investments in India at Biopharma Conclave 2025

Hyderabad: Thermo Fisher Scientific announced plans to make significant investments in India’s biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. The announcements came when senior executives addressed government, industry and academia at the Biopharma Conclave 2025.

In 2024, India’s biopharmaceutical market was $8.1 billion in size, and is expected to almost double to $15.9 billion in 2030. Key drivers of this growth include increasing market maturity, forthcoming environment for regulatory approvals globally, and high-unmet clinical needs within India.

“India’s biopharma sector is poised for a giant leap, and we are deeply committed to enabling that outcome,” said Tony Acciarito, President, Asia Pacific & Middle East, Africa, Thermo Fisher Scientific. “Our integrated solutions, from research to manufacturing, will help our customers innovate faster, increase productivity and maintain the highest quality standards. India is one of our fastest-growing markets, and we are building capacity and capabilities here to match its immense potential.”

Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, both set to open by year-end 2025. The Bioprocess Design Center (BDC), developed in partnership with the Telangana Government, will provide expertise in bioprocessing and process scale-up to accelerate development of life-changing therapies.

Complementing the BDC, Thermo Fisher’s Customer Experience Center (CEC) will showcase advanced instrumentation and workflow solutions across molecular biology, proteomics, clinical diagnostics, cell and gene therapy among others. Subject matter experts will support method development, technology adoption, and industry upskilling.

“India’s biopharma industry currently faces challenges which include access to cutting-edge technologies and technology experts. The BDC and CEC will help directly address them, enabling both start-ups and established companies to reduce time-to-market. Therapies will meet stringent international quality requirements through this collaborative ecosystem”, added Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific.

The conclave, which was organised by CPHI, Informa Markets (a division of Informa PLC), included discussions on priorities such as biologics and cell and gene therapy advancement, workforce development, and advancing women in STEM fields.

A leadership panel on building sustainable and profitable biologics and biosimilars businesses amidst uncertainty covered current pipeline and outlook for the next five years.